Deals1 Jul 2024, 10:45 pm
Lupin Limited Completes Transfer of Trade Generics Business in India to Subsidiary
AI Summary
On July 1, 2024, Lupin Limited successfully completed the transfer of its trade generics business in India to its wholly owned subsidiary, Lupin Life Sciences Limited, as a going concern on a slump sale basis. This transaction was initially announced on June 7, 2024, when the Company entered into a Business Transfer Agreement with Lupin Life Sciences Limited to carve out its trade generics business in India. This disclosure is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Highlights
- Lupin Limited completes the transfer of its trade generics business in India to Lupin Life Sciences Limited.
- The transaction was carried out as a going concern on a slump sale basis.
- The Company entered into a Business Transfer Agreement on June 7, 2024, to carve out its trade generics business in India.
- This disclosure is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The transaction has been completed on July 1, 2024.